Cited by — Overall survival and long-term outcomes from the randomized, double-blind, placebocontrolled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Overall survival and long-term outcomes from the randomized, double-blind, placebocontrolled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.
No admitted local citation edges point to this work yet.
